Long Term Outcomes After Vestibular ImplantationClinical TrialClinicalTrials.govPublished Dec 1, 2024Added May 27, 2026
Not reported in abstract.
Phase: NAStatus: RECRUITING
MOTS-C
Mitochondrial-Derived Peptide | Metabolic Regulator
LongevityMetabolic
Well Studied
### Summary MOTS-C is a mitochondrial-derived peptide that has garnered attention for its potential roles in metabolic regulation and cellular stress responses. Emerging research suggests it may have implications in various health conditions, including cardiovascular diseases and placental function.
Community effect ratings, structured research logs, and side-effect patterns — all fed by one anonymous form.
Effect profile (overview)
Aggregate AI baseline blended with community voting. Hover to inspect effect strengths per category.
Effect scores blend an AI baseline with community ratings. Open the full chart for per-category detail; rate via the Contribute button.
Research log summary heatmap
Compact view of how logs describe shifts in pain, sleep, and performance (−5 to +5). Treat this as qualitative, anonymous signal only.
No community research logs yet. When structured logs are added, this panel will summarize typical shifts in pain, sleep, and performance.
Anonymous side-effect patterns
Rough heatmap of anonymous side-effect and positive-signal tags — a "most-mentioned" snapshot, not safety or efficacy advice.
No anonymous side-effect reports yet. When reports are submitted, this panel will show a simple heatmap of tags like "nausea", "flushing", "improved healing", and more.
Research footprint
Last analyzed Jul 17, 20263
Studies indexed
1
Human
1
Animal
3
AI analyzed
Evidence mix33% human · 33% animal · 0% cellular · 0% review
Highest phase: PreclinicalYears covered: 2023
Librarian pulse — latest actionsFull changelog ↓
- Jul 16, 3:59 PMRe-scoredSeeded effect profile for MOTS-C
- Jul 16, 6:00 AMRefreshedRefreshed content for MOTS-C
- Jul 15, 6:00 AMRefreshedRefreshed content for MOTS-C
Research & intelligence feed
Studies, clinical trials, community discussions, and news.
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of MOTS-c (a Mitochondrial-Derived Peptide) in Adults With Prediabetes and Overweight/ObesityClinical TrialClinicalTrials.govPublished Feb 2, 2026Added Apr 16, 2026
This study evaluated the efficacy, safety, and pharmacodynamics of MOTS-C in adults with prediabetes and overweight/obesity. The study was a Phase 2a, randomized, double-blind, placebo-controlled trial. Not reported in abstract.
Phase: PHASE2Status: RECRUITING
High On-treatment Platelet Reactivity, Increased B-amyloid and Downregulation of MOTS-c Predict Mortality in Patients With Coronary Artery Disease and Type 2 Diabetes Mellitus: a 2-year Follow up StudyClinical TrialClinicalTrials.govPublished Jan 1, 2014Added Apr 16, 2026
This study evaluated the relationship between on-treatment platelet reactivity, B-amyloid levels, and MOTS-C downregulation in patients with coronary artery disease and type 2 diabetes mellitus over a two-year follow-up period. The findings suggest associations with mortality, but specific numeric outcomes are not detailed in the abstract. No therapeutic claims are made.
Status: UNKNOWN
Cohort of Universal Newborn Deafness-gene Screening in Nantong City, ChinaClinical TrialClinicalTrials.govPublished Jan 1, 2016Added Apr 16, 2026
Not reported in abstract.
Status: ACTIVE_NOT_RECRUITING
A Pilot Study: The Effect of Longitudinal Exercise Programming in Breast Cancer PatientsClinical TrialClinicalTrials.govPublished Aug 28, 2019Added Apr 16, 2026
This pilot study investigated the effects of longitudinal exercise programming in breast cancer patients. The specific outcomes measured were not detailed in the abstract. The study's findings regarding the impact of exercise on this population remain unspecified.
Phase: NAStatus: COMPLETED
The Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination on Endothelial Function, Arterial Stiffness and Left Ventricular Deformation in Patients With Type 2 Diabetes With High Cardiovascular RiskClinical TrialClinicalTrials.govPublished Nov 3, 2017Added Apr 16, 2026
This study assessed the effects of GLP-1 agonists, SGLT2 inhibitors, and their combination on endothelial function, arterial stiffness, and left ventricular deformation in patients with type 2 diabetes at high cardiovascular risk. The specific doses and outcomes measured were not detailed in the abstract. The findings may have implications for cardiovascular health in this patient population.
Status: RECRUITING
Semantic Scholar search for MOTS-CStudySemanticScholarAdded Dec 12, 2025
Not reported in abstract.
MOTS‑c protects against placental injury via Nrf2 activation in hypoxia‑induced intrauterine growth restriction mice.StudyPubMedPublished Jan 1, 2023Added Dec 12, 2025
MOTS-C may protect against placental injury in a mouse model of hypoxia by activating Nrf2, but further research is needed to confirm these effects in humans.
Circulating Mitochondrial Open Reading Frame of the 12S Ribosomal RNA Type-c Is Higher in Acute Coronary Syndrome and Is a Prognostic Biomarker for Major Cardiac Events in Patients With Acute Myocardial Infarction: A Case-Control Study.StudyPubMedPublished Jan 1, 2023Added Dec 12, 2025
MOTS-C levels may be higher in patients with acute coronary syndrome, but specific outcomes and clinical significance are not detailed in the abstract.
External databases
Helpful external resources for additional structural, pharmacologic, and literature context. These are third-party databases; always cross-check details with primary research.
Practical guides for MOTS-C
How-to and safety articles applicable to every peptide in the library.
- Reconstitution calculatorCompute BAC water volume and syringe units for any dose.
- BAC water guideWhat bacteriostatic water is and why peptides need it.
- How to reconstitute peptidesStep-by-step mixing protocol with a worked example.
- How to inject peptidesSubcutaneous injection technique with insulin syringes.
- Where to inject peptidesSite selection, rotation, and pinch technique.
- Safety overviewSide-effect data, regulatory status, and red-flag risks.
Articles mentioning MOTS-C
- Best Peptides for Energy: Mitochondrial and Metabolic SupportPeptides studied for energy, mitochondrial function, and exercise capacity — NAD+, MOTS-c, AICAR, SS-31, SLU-PP-332 — with what each does and what's realistic.roundup · 4 min
- Anti-Aging Peptide Stack: What the Evidence Actually SupportsMost 'anti-aging peptide stacks' over-promise. Here's a defensible combination — NAD+, GHK-Cu, Epitalon, SS-31 — with what each does, what the evidence supports, and what's speculative.stack · 6 min
- Best Peptides for Anti-Aging: Evidence-Backed RankingThe peptides with the strongest evidence for aging-related endpoints — Epitalon, NAD+, GHK-Cu, SS-31, FOXO4-DRI — with what each does and realistic expectations.roundup · 4 min
- Best Peptides for Fat Loss: Evidence-Based RoundupRanked roundup of peptides studied for fat loss — GLP-1 / GIP agonists, GH-axis fragments, and supporting metabolic peptides — with mechanism, evidence quality, and how to choose.weight-loss · 6 min
- SLU-PP-332 Explained: The 'Exercise Mimetic' ERR AgonistSLU-PP-332 is a synthetic pan-ERR agonist that mimics endurance-exercise gene expression in animal models. Here's what's actually known, what's speculative, and why caution is warranted.news · 4 min
Community notes
No comments yet. Share research notes, citations, or observations below.
Community research logs (detail)
No community research logs yet. Use the “Contribute data” button above to share an anonymized summary of your experience.
Anonymous side-effect reporting (detail)
This section describes how anonymous side-effect reports are aggregated into the heatmap above. Reports are anonymous and unverified, and should be read alongside primary safety data.
Use the "Report side effects" button to open a focused popup form. Please keep descriptions neutral and avoid medical language; think in terms of "nausea", "flushing", "vivid dreams", etc.
Librarian Changelog
Every time the Librarian touches this peptide — discovering, refreshing, scoring, or verifying — it logs the action here.
1d agoScoringbackfill70%
Seeded effect profile for MOTS-C
1d agoRefreshai-researcher85%
Refreshed content for MOTS-C
2d agoRefreshai-researcher85%
Refreshed content for MOTS-C
3d agoRefreshai-researcher85%
Refreshed content for MOTS-C
4d agoRefreshai-researcher85%
Refreshed content for MOTS-C
5d agoRefreshai-researcher85%
Refreshed content for MOTS-C
6d agoRefreshai-researcher85%
Refreshed content for MOTS-C
Jul 10Refreshai-researcher85%
Refreshed content for MOTS-C
Jul 9Refreshai-researcher85%
Refreshed content for MOTS-C
Jul 8Refreshai-researcher85%
Refreshed content for MOTS-C
Jul 7Refreshai-researcher85%
Refreshed content for MOTS-C
Jul 6Refreshai-researcher85%
Refreshed content for MOTS-C
Jul 5Refreshai-researcher85%
Refreshed content for MOTS-C
Jul 4Refreshai-researcher85%
Refreshed content for MOTS-C
Jul 3Refreshai-researcher85%
Refreshed content for MOTS-C
Jul 2Refreshai-researcher85%
Refreshed content for MOTS-C
Jul 1Refreshai-researcher85%
Refreshed content for MOTS-C
Jun 30Refreshai-researcher85%
Refreshed content for MOTS-C
Jun 29Refreshai-researcher85%
Refreshed content for MOTS-C
Jun 28Refreshai-researcher85%
Refreshed content for MOTS-C